Barentz International, a global speciality pharmaceutical ingredients provider, has acquired Anshul Life Sciences Group in India.
Barentz has acquired the pharmaceutical chemicals distributor to bolster its presence in India, while also providing Indian customers with technical expertise.
The company’s move into India was strategically made owing to the high growth potential of the Asia Pacific pharmaceutical market.
Anshul Life Sciences’ distribution capabilities will complements Barentz’s ingredients portfolio of excipients, APIs and intermediates, while also widening its personal care and nutraceutical offerings.
The CEO of Anshul, Nagarajan Kailasam, will continue to run the businesses’ operations.
CEO of Barentz’s APAC division, Marc Duchene, commented: “This acquisition will allow us to further grow in India — one of our key strategic markets — and the Asia Pacific region in general. The acquisition benefits our customers and principals by providing access to a broader portfolio of high-quality pharmaceuticals excipients and products and a deeper pool of expertise. We are delighted that Mr Nagarajan will continue to lead the business. Together, we aim to enhance our offering and better serve the needs of the dynamic Indian market and beyond.”
CEO of Anshul Life Sciences, Nagarajan Kailasam, stated: “Barentz aligns strongly with the entrepreneurial spirit and ethical standards of Anshul Life Science’s founding partners. We are excited to join the Barentz family and start our collaboration to capture the enormous potential of the Indian market by offering even more comprehensive solutions to our customers and principals in the Indian market and beyond. We are looking forward to the future and the growing international reach that this strategic move will bring to Anshul Life Sciences.